Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease

Eur J Hosp Pharm. 2022 Nov;29(6):e8. doi: 10.1136/ejhpharm-2021-002694. Epub 2021 Feb 4.

¹ Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
² Medfuture Research Center for Advanced Medicine, Iuliu HaTieganu University of Medicine and Pharmacy Faculty of Medicine, Cluj Napoca, Romania.
³ Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania.
⁴ Department of Genetics, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania.
⁵ Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania ciprian.tomuleasa@umfcluj.ro.

No abstract available

Keywords: allergy and immunology; chemistry; clinical; clinical medicine; hematology; virology.

Publication types